Auvi-Q (epinephrine injection, USP): Recall – Potential Inaccurate Dosage Delivery

breaking medical news

Bridgewater, N.J. – Sanofi US is voluntarily recalling all Auvi-Q® (epinephrine injection, USP). The recall involves all Auvi-Q currently on the market and includes both the 0.15 mg and 0.3 mg strengths for hospitals, retailers and consumers. This includes lot number 2299596 through 3037230, which expire March 2016 through December 2016. The products have been found to potentially have inaccurate dosage delivery.

FDA approved ipilimumab (Yervoy  Injection), for the additional indication of adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.  October 28, 2015.  More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm470061.htm

Allergan plc Confirms Discussions Regarding Potential Business Combination Transaction With Pfizer Inc.

DUBLIN, Oct. 29, 2015 /PRNewswire/ — Allergan plc today confirmed that it has been approached by Pfizer Inc. and is in preliminary friendly discussions regarding a potential business combination transaction. Allergan stated that no agreement has been reached and there can be no certainty that these discussions will lead to a transaction, or as to the terms on which a transaction, if any, might be agreed.  The company will not comment on speculation regarding the terms of a potential transaction. read more

Quest Medical, Inc. Issues Recall of MPS® Delivery Set

On October 28, 2015, Quest Medical, Inc. initiated a nationwide recall of Myocardial Protection System (MPS) Delivery Sets, Models 5001102, 5001102-AS, and 7001102 of specified lots. The product(s) have been found to intermittently exhibit a seal failure during use, which potentially could result in patient blood loss. read more

Valeant To Terminate Relationship With Philidor

LAVAL, Quebec, Oct. 30, 2015 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that it is severing all ties with Philidor Rx Services, LLC, and that Philidor has informed Valeant that it will shut down operations as soon as possible, consistent with applicable laws. read more

U.S. District Court Denies Perrigo’s Motion for Preliminary Injunction Related to Certain Mylan Disclosures

HERTFORDSHIRE, England and PITTSBURGH, Oct. 30, 2015 /PRNewswire/ — Mylan N.V. (Nasdaq: MYL) today announced that the U.S. District Court for the Southern District of New York has denied the motion by Perrigo Company plc (NYSE: PRGO; TASE) for a preliminary injunction concerning Mylan’s proposed acquisition of Perrigo, ruling that Mylan had provided adequate public disclosures regarding the synergies expected to be achieved from the combination. read more

MiMedx Comments on Recent FDA Draft Guidance on Homologous Use of HCT/Ps

MARIETTA, Ga., Oct. 29, 2015 /PRNewswire/ — MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, commented on the proposed Draft Guidance on Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products (“HCT/Ps”) that the Food and Drug Administration (“FDA”) published for comment on October 28, 2015 and the Notice of Public Hearing and Request for Comments released today indicating the agency would hold a public hearing on April 13, 2016 to obtain input on that Guidance as well as three other recently issued guidance documents on HCT/Ps .read more

Myocardial Protection System (MPS) Delivery Sets by Quest Medical: Recall – Intermittent Seal Failure During Use

The identified lots of MPS Delivery sets have shown a possible seal failure along the blood source channel of main pump cassette, resulting in blood loss from the bypass circuit and interruption of cardioplegia solution delivery. The firm has received twenty complaints alleging this seal failure which have resulted in 16 instances of patient blood loss during surgery. There have been no reports of patient injuries as a result of the alleged issue to date.

Recalled Product(s) were manufactured from May 2015 to September 2015 and distributed from June 2015 to September 2015. read more

AbbVie Outlines Long-Term Strategic and Financial Objectives; Company Positioned for Strong Performance

Company Expects to Deliver Double-Digit Adjusted Earnings-Per-Share (EPS) Growth on Average Through 2020
– Guides to Total Company Sales of Approximately $37 Billion in 2020
– Targeting 2020 Global HUMIRA Sales of More Than $18 Billion and IMBRUVICA Revenue of Approximately $5 Billion
– Expects Significant Margin Expansion; Targeting 2020 Operating Margin of Greater Than 50 Percent, with an Average of 100-200 Basis Points of Improvement Per Year
– On Track to Launch More Than 20 New Products or Indications Through 2020; Pipeline Has Potential to Deliver Nearly $30 Billion in Nominal Peak-Year Sales
– Committed to Returning Cash to Shareholders Through a Strong and Growing Dividend; Increases 2016 Dividend by 12 Percent, Beginning with Dividend Payable in February 2016
– Provides 2016 Adjusted EPS Guidance of $4.90 to $5.10 Reflecting Strong Double-Digit Growth Versus 2015
– Company to Host Comprehensive R&D Pipeline Review in Chicago During 2016 ASCO Meeting read more
 Celgene’s VIDAZA® (Azacitidine for Injection) Approved by the European Commission as New Treatment for Elderly Patients with Acute Myeloid Leukaemia

BOUDRY, Switzerland–(BUSINESS WIRE)–Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that the European Commission (EC) has approved VIDAZA® (azacitidine for injection) for the treatment of adult patients aged 65 years or older with acute myeloid leukaemia (AML) who are not eligible for haematopoietic stem cell transplantation (HSCT). read more

Sosei Confirms FDA Approvals of New Dual Combination Bronchodilator Utibron™ Neohaler® and Monotherapy Seebri™ Neohaler® for Patients with Chronic Obstructive Pulmonary Disease

TOKYO–(BUSINESS WIRE)–Sosei Group Corporation (TOKYO:4565) confirms today that the US Food and Drug Administration (FDA) has approved the new Novartis dual combination bronchodilator Utibron™ Neohaler® (indacaterol 27.5 mcg/glycopyrrolate 15.6 mcg) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. The FDA also approved Seebri™ Neohaler® (glycopyrrolate) inhalation powder 15.6 mcg – which is one component of Utibron Neohaler – as a stand-alone monotherapy for COPD. Sosei is eligible to receive milestone payments of 22.5 million dollars for approval of both products. read more

 

 

 

Subscribe today for leading medical news and career advice from top  medical recruiters!

Subscribe today for leading medical news and career advice from top medical recruiters!

 

 

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.